Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Asahi_Kasei
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:CEO |
Craig Collard
|
| gptkbp:country |
gptkb:Denmark
|
| gptkbp:focusesOn |
transplant medicine
|
| gptkbp:formerName |
LifeCycle Pharma
|
| gptkbp:founded |
2002
|
| gptkbp:headquartersLocation |
gptkb:Hørsholm,_Denmark
|
| https://www.w3.org/2000/01/rdf-schema#label |
Veloxis Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Envarsus_XR
|
| gptkbp:parentCompany |
gptkb:Asahi_Kasei
|
| gptkbp:specializesIn |
immunosuppressive drugs
|
| gptkbp:stockExchange |
gptkb:Nasdaq_Copenhagen_(delisted)
|
| gptkbp:website |
https://www.veloxis.com/
|
| gptkbp:bfsParent |
gptkb:Astellas_Pharma_Inc.
gptkb:Envarsus_XR |
| gptkbp:bfsLayer |
7
|